Metastatic Squamous Cell Carcinoma: What Is the Survival Rate?

Survival rates for metastatic squamous cell carcinoma range from a few months to several years, depending heavily on where the original cancer started, how many sites it has spread to, and whether the tumor responds to newer immunotherapy drugs. There is no single number that captures the prognosis, because “squamous cell carcinoma” is really a family of cancers arising in different organs, each with its own biology and treatment options. Understanding which factors push the odds in one direction or the other is where the practical value lies.

Why One Number Cannot Answer the Question

Squamous cell carcinoma can originate in the skin, the lining of the mouth and throat, the esophagus, the lungs, the cervix, and several other sites. Once it becomes metastatic, meaning it has spread beyond the original organ to distant parts of the body, each type follows a different trajectory. Metastatic skin squamous cell carcinoma carries a five-year disease-specific survival around 79%, which is far better than most people expect from the word “metastatic.”¹ By contrast, metastatic esophageal squamous cell carcinoma has a median survival of roughly five to seven months, with only about one in ten patients alive at two years.² Metastatic head and neck squamous cell carcinoma falls somewhere in between, with median overall survival historically around seven to eleven months on standard chemotherapy, though that number has shifted upward with immunotherapy.

Because of this spread, any survival statistic you encounter needs to be read alongside the specific cancer type and the specific treatment being discussed. A blanket “metastatic SCC survival rate” is almost meaningless without that context.

Metastatic Cutaneous Squamous Cell Carcinoma

Skin SCC is extremely common, but only a small fraction of cases ever metastasize. When it does spread, the prognosis is surprisingly variable. A nationwide registry study in the Netherlands found that about 15% of patients with metastatic cutaneous SCC died of their disease, yielding a five-year disease-specific survival of roughly 79%.¹ That figure is better than many solid tumors even before they metastasize, largely because “metastatic” in the skin cancer context often means spread to regional lymph nodes rather than distant organs.

The risk factors that predict worse outcomes in metastatic skin SCC include older age, male sex, and being immunosuppressed. Organ transplant recipients, for instance, face roughly five times the hazard of disease-specific death compared to immunocompetent patients.¹ A prospective cohort study also identified thick tumors (six millimeters or deeper) and a particular growth pattern called desmoplastic growth as strong predictors of dying from the disease.³

The arrival of immunotherapy has reshaped treatment for advanced skin SCC. Cemiplimab, a PD-1 inhibitor, produced tumor responses in about 47% of patients with metastatic cutaneous SCC in a phase 2 trial, and among those who responded, over 80% were still responding at the time the data were analyzed.⁴ Pembrolizumab, another PD-1 blocker, showed durable antitumor activity in both locally advanced and metastatic skin SCC without unexpected safety signals.⁵ These drugs have become standard care for metastatic skin SCC that is not suitable for surgery or radiation, and they have meaningfully improved what patients can expect.

Metastatic Head and Neck Squamous Cell Carcinoma

Head and neck SCC is where survival statistics have changed the most dramatically in recent years. Historically, the standard first-line treatment for recurrent or metastatic disease was platinum-based chemotherapy combined with the targeted drug cetuximab. That regimen pushed median overall survival from about seven months with chemotherapy alone to about ten months.⁶ A decade ago, surviving even a year with metastatic head and neck SCC was not the norm.

The KEYNOTE-048 trial changed the treatment landscape. In patients whose tumors expressed higher levels of PD-L1, pembrolizumab alone extended median survival to nearly 15 months compared with about 11 months on the old cetuximab-chemotherapy standard. When pembrolizumab was combined with chemotherapy, the benefit extended across the broader population as well, with median survival reaching 13 months versus about 11 months for the old regimen.⁷ Five-year follow-up data from the same trial are striking: about 16% of patients given pembrolizumab plus chemotherapy were alive at five years, compared with roughly 5% in the older treatment arm.⁸ That tail of long-term survivors is something chemotherapy alone almost never produced.

A reasonable question is whether those clinical trial results hold up in everyday practice. A comparison of real-world immunotherapy outcomes against the KEYNOTE trial data found no significant difference in overall survival, suggesting that the trial results translate reasonably well outside of research settings.⁹

HPV Status Makes a Measurable Difference

Among head and neck cancers, whether the tumor is linked to the human papillomavirus changes the prognosis substantially. A systematic review and meta-analysis of recurrent or metastatic head and neck SCC found that HPV-positive patients had a weighted average overall survival of about 21 months when treated in the first-line setting, compared with about 12 months for HPV-negative patients.¹⁰ In trials from the Eastern Cooperative Oncology Group, the gap was equally clear: median survival was roughly 13 months for HPV-positive patients versus about 7 months for HPV-negative patients.¹¹

The HPV advantage is not uniform across all head and neck sites, though. A study looking specifically at metastatic pharyngeal cancers found that the survival benefit of HPV positivity was concentrated in oropharyngeal tumors (those arising in the tonsils and base of tongue) but not in pharyngeal cancers from other sub-sites. Among oropharyngeal patients, the benefit was strongest in those with only a few metastatic sites rather than widespread disease.¹² So HPV status is a powerful prognostic marker, but it matters most in the right combination of tumor location and metastatic burden.

How the Number and Location of Metastases Shape Outcomes

Perhaps the single most influential factor after cancer type is how much the disease has spread. In head and neck SCC, patients with what clinicians call oligometastatic disease, usually defined as a small number of metastatic sites (often one to three), live dramatically longer than those with widespread metastases. One study found that patients with oligometastatic HPV-positive oropharyngeal cancer had a median survival of 45 months, compared with just 10 months for those with polymetastatic disease.¹³ A separate study of metastatic head and neck SCC treated with metastasis-directed therapy reported a five-year survival of 35% for patients with a single metastasis, versus only 4% for those with multiple metastases.¹⁴

Where the cancer lands also matters. A population-based study of lung squamous cell carcinoma found that metastases to the brain, bone, and liver each carried a higher risk of death than metastases confined to the lung itself.¹⁵ For head and neck SCC specifically, independent prognostic factors at initial diagnosis included the presence of bone, brain, liver, or lung metastases, along with the primary tumor’s site and stage.¹⁶ In general, liver and brain metastases carry the worst prognosis, while isolated lung metastases are more amenable to focused treatment.

Treating Oligometastatic Disease Aggressively

The recognition that patients with only a few metastatic sites behave differently has led to a growing interest in treating those sites directly, on top of systemic therapy. High-dose focused radiation, often called stereotactic body radiation therapy, is the most studied approach. A single-institution series of oligometastatic head and neck SCC patients treated with this technique reported a median overall survival of about 1.9 years, with 78% alive at one year and 43% at two years.¹⁷ Another study comparing focused radiation plus systemic therapy against systemic therapy alone found two-year survival rates of 29% versus 15%, though the difference did not reach statistical significance in that small sample.¹⁸

Among patients whose metastases were treated directly, those treated at a single metastatic site after metastasis-directed therapy had a five-year survival around 31%.¹⁴ These numbers are far better than historical expectations for metastatic head and neck cancer and suggest that selecting the right patients for aggressive local treatment can meaningfully extend life, even if the disease eventually progresses elsewhere.

Metastatic Esophageal Squamous Cell Carcinoma

Among all the squamous cell carcinomas, esophageal SCC with distant metastases carries one of the bleakest prognoses. A population-based study found a median overall survival of about seven months for younger patients and five months for those diagnosed at older ages. Only about 13% and 9%, respectively, were alive at two years.² The site of metastasis also influences prognosis in esophageal SCC, with different distant sites leading to different outcomes, and multimodality treatment including chemotherapy along with possible surgery or radiation has been shown to improve survival compared with single-modality approaches.¹⁹

How Survival Has Changed Over Decades

It is worth stepping back to see the larger trend. A study tracking outcomes in metastatic head and neck SCC over 30 years found that five-year disease-specific survival improved from 57% during 1987–1996 to 88% during 2007–2016, even after adjusting for patient age and other risk factors.²⁰ Those decades saw the introduction of cetuximab, the spread of intensity-modulated radiation, better surgical techniques, and eventually immunotherapy. Each incremental advance shifted the survival curve upward. The most recent leap, the five-year KEYNOTE-048 data showing that roughly one in six patients on pembrolizumab-chemotherapy are alive at five years, is the latest installment in a trajectory that shows no signs of leveling off.⁸

Biomarkers That Predict Who Will Respond

Knowing the average survival is useful, but patients and their oncologists increasingly want to know whether a specific person is likely to benefit from a given treatment. PD-L1 expression, measured as a combined positive score, is the most established biomarker in head and neck SCC. In the KEYNOTE-048 data, patients with higher PD-L1 scores saw bigger survival gains from pembrolizumab.⁷ A separate study of nivolumab, another PD-1 inhibitor, found that patients with a combined positive score of 15 or higher had a median progression-free survival of 13 months, significantly better than those with lower scores.²¹

Circulating tumor DNA, or ctDNA, is an emerging tool. This is tumor-derived DNA that leaks into the bloodstream and can be measured with a blood draw rather than a biopsy. In locally advanced head and neck SCC, patients who still had detectable ctDNA after treatment had significantly worse survival, and the ctDNA signal turned positive a median of seven months before clinical recurrence was detected by imaging.²² In the metastatic setting, a drop in ctDNA after one cycle of treatment predicted both progression-free and overall survival, and even identified patients who lived longer despite initial imaging that looked discouraging.²³ A meta-analysis focused on HPV-negative head and neck cancer linked ctDNA mutations in the TP53 gene and methylation changes in specific genes to worse survival outcomes.²⁴ While ctDNA testing is not yet standard in routine clinical care for most SCC types, it is moving in that direction and could eventually help oncologists tailor treatment more precisely.

Antibody-Drug Conjugates on the Horizon

Beyond PD-1 inhibitors, a newer class of drugs called antibody-drug conjugates is generating interest. These work by attaching a toxic chemotherapy payload to an antibody that targets a protein found on cancer cells, delivering the poison directly to the tumor while sparing healthy tissue. A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck SCC found that response rates for antibody-drug conjugate monotherapy reached about 47%, with individual agents like MRG003 showing response rates in the low to mid-40% range.²⁵ These drugs are still in clinical trials for most head and neck SCC indications, but the response rates are encouraging, particularly for patients whose disease has progressed on immunotherapy.

The treatment pipeline also includes bispecific antibodies, which simultaneously engage two targets and can redirect the patient’s own immune cells to the tumor. Early results vary widely, with response rates ranging from zero to over one-third depending on the specific agent and combination, but the field is moving fast. For patients whose cancers stop responding to current options, these newer approaches represent a genuine reason for cautious optimism.

The Biology Behind Metastatic Spread

Squamous cell cancers spread when tumor cells undergo changes that allow them to detach from the primary tumor, invade surrounding tissue, enter the bloodstream or lymphatic system, and seed new tumors elsewhere. A key process driving this is called epithelial-mesenchymal transition, in which cancer cells lose the sticky adhesion molecules that hold them in place and gain properties that allow them to migrate. Research in oral squamous cell carcinoma has shown that this involves a switch in the type of cadherin molecules the cells produce, along with activation of specific signaling pathways.²⁶ One study found that a protein called SIRT1 can actually inhibit this migration process in oral SCC cells by interfering with signaling that promotes invasion, pointing toward possible future therapeutic targets.²⁷

Understanding this biology matters for survival because it helps explain why some tumors metastasize early and aggressively while others never spread. Tumors with features suggesting more complete mesenchymal transition, such as poorly differentiated cells and desmoplastic growth patterns, tend to behave worse. The stage of the original tumor and how rapidly it was growing are stronger predictors of survival than how long a patient waited before seeking medical attention, which is a common worry that turns out to be less important than the tumor’s intrinsic biology.²⁸